At‐Home Versus in‐Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform Trial
Muscle & Nerve · 2026-09 · 74 (3) · 702-708
DOI: 10.1002/mus.70322 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Muscle & Nerve, online erschienen am 28.06.2026. Verfasst von Eric A Macklin und 22 weiteren Autor:innen. Beteiligte Einrichtung: Sean M. Healey and AMG Center for ALS & the Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Muscular Dystrophy Association, Tackle ALS, ALS Finding a Cure.
Abstract (Originalsprache)
Introduction/Aims Respiratory weakness, typically monitored as vital capacity (VC), is a central feature of amyotrophic lateral sclerosis (ALS). VC is increasingly measured remotely in participants' homes, although in‐clinic assessment remains the standard. We tested concordance between at‐home and in‐clinic VC to determine trial eligibility, track progression, and predict survival in a large ALS trial.
Methods
At‐home and in‐clinic VC were assessed at baseline and approximately every 8 weeks for a year in the first four regimens of the HEALEY ALS Platform Trial. At‐home assessments were coached via live videoconference and centrally reviewed. VC measurements, expressed as percent of predicted normal (% PN ), were compared cross‐sectionally, longitudinally, and for predicting survival time. Data from 233 participants with 3–8 paired at‐home and in‐clinic VC assessments completed < 14 days apart were analyzed.
Results
At‐home and in‐clinic VC were well correlated (Lin's r c = 0.82) with no systematic bias. At‐home VC ≥ 60% PN predicted in‐clinic VC ≥ 60% PN with a positive predictive value of 91% and a negative predictive value of 65%. VC slopes were moderately correlated ( r c = 0.68). At‐home VC progressed 28% faster than in‐clinic VC with proportionately less variance (at‐home [ SE ] = −1.882 [0.153] % PN /month, in‐clinic = −1.476 [0.131] % PN /month). Slopes of at‐home and in‐clinic VC explained 15% and 17% of variation in future survival time, respectively.
Discussion
At‐home and in‐clinic VC were well correlated cross‐sectionally. At‐home VC performed well tracking longitudinal change and predicting survival. The reduced participant burden of assessment and concordance with in‐clinic measurement support use of at‐home monitoring of VC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sean M. Healey and AMG Center for ALS & the Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.
- Massachusetts General Hospital Biostatistics, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Barrow Neurological Institute, Phoenix, Arizona, USA.
- Department of Neurology and the ALS Center, Miller School of Medicine, University of Miami, Miami, Florida, USA.
- Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
ORCID-Profile: Erica Scirocco, Zachary Simmons, Sabrina Paganoni
Förderung
- Muscular Dystrophy Association
- Tackle ALS
- ALS Finding a Cure
- ALS Association
- ALS ONE
- The Arthur M. Blank Family Foundation
- The AMG Charitable Foundation
Zitieren
APA
Macklin, E. A., Berry, J. D., Harkey, B. A., Heyd, L., Chase, M., Yu, H., Sherman, A. V., Dagostino, D., Kittle, G., Hall, M., Connolly, M. R., Drake, K., Giacomelli, E., Scirocco, E., Sharma, S., Babu, S., Benatar, M., Simmons, Z., Young, E., …, & HEALEY ALS Platform Trial Study Group (2026). At‐Home Versus in‐Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform Trial. Muscle & Nerve, 74(3), 702-708. https://doi.org/10.1002/mus.70322
Vancouver
Macklin EA, Berry JD, Harkey BA, Heyd L, Chase M, Yu H, et al. At‐Home Versus in‐Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform Trial. Muscle & Nerve. 2026;74(3):702-708. doi:10.1002/mus.70322
BibTeX
@article{Macklin2026,
author = {Macklin, Eric A and Berry, James D and Harkey, Brittney A and Heyd, Lindsay and Chase, Marianne and Yu, Hong and Sherman, Alexander V and Dagostino, Derek and Kittle, Gale and Hall, Meghan and Connolly, Mariah R and Drake, Kristin and Giacomelli, Elisa and Scirocco, Erica and Sharma, Saloni and Babu, Suma and Benatar, Michael and Simmons, Zachary and Young, Eufrosina and Cudkowicz, Merit E and Shefner, Jeremy and Paganoni, Sabrina and HEALEY ALS Platform Trial Study Group, HEALEY ALS Platform Trial Study Group},
title = {At‐Home Versus in‐Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform Trial},
journal = {Muscle & Nerve},
year = {2026},
volume = {74},
number = {3},
pages = {702--708},
doi = {10.1002/mus.70322}
}
EUVIMED